Radionuclide Therapy: Chemistry and Applications

Targeted radionuclide therapy is a successful but under-used cancer treatment modality, offering opportunities for design and synthesis of agents incorporating radionuclides from all parts of the periodic table. The aim of this meeting is to bring chemists and radiobiologists together with practitioners of radionuclide therapy including physicians, radiopharmacists and medical physicists to enhance interdisciplinary awareness and identify areas for chemical development that will widen the clinical use and improve efficacy of radionuclide therapy.

Speakers:
Professor Mike Zalutsky (Duke University, North Carolina, USA)
Professor Steve Mather (Cancer Research UK, London, UK)
Dr Val Lewington (Royal Marsden Hospital, Sutton, UK)
Dr John Buscombe (Royal Free Hospital, London, UK)
Professor Alan Perkins (University of Nottingham, UK)
Professor Jon Dilworth (University of Oxford, UK)
Dr Kim Orchard (Southampton General Hospital, UK)
Professor Rob Mairs (Beatson Institute, Glasgow, UK)